The company has received notifications about transactions in the Issuer's securities.
The person authorized to provide additional information:
INVL Technology Managing Partner
The company has received notifications about transactions in the Issuer's securities.
The person authorized to provide additional information:
INVL Technology Managing Partner
HomeServices of America, a Berkshire Hathaway affiliate, has welcomed iconic leaders Steven James and Brad Loe to the company’s leadership team.
The scope of accreditation for Intertek's North American PPE Center of Excellence has been expanded to include testing face coverings to ASTM F3502.
At least two groups of China-linked hackers have spent months using a previously undisclosed vulnerability in American networking devices to spy on the U.S. defense industry, researchers and the devices' manufacturer said Tuesday. Utah-based IT company Ivanti said in a statement that the hackers took advantage of the flaw in its Pulse Connect Secure suite of virtual private networking devices to break into the systems of "a very limited number of customers." Ivanti said https://kb.pulsesecure.net/pkb_mobile#article/l:en_US/SA44784/s that while it was taking steps to mitigate the compromises a fix for the issue would not be available until early May.
Acumen Research and Consulting, a global provider of market research studies, recently added a forthcoming report titled “Thyroid Cancer Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2021 - 2030” gives insights about Thyroid Cancer MarketLOS ANGELES, April 20, 2021 (GLOBE NEWSWIRE) -- Thyroid cancer occurs in the cells of the thyroid, the mutations allow the cells to grow and multiply rapidly. The cells also lose the ability to die, as normal cells would. Thyroid Cancer Market Segment Analysis, 2019 The global thyroid cancer market is segmented into type, technique, and end use. The type segment is bifurcated into papillary carcinoma, follicular carcinoma, and others. Among type the papillary carcinoma segment is expected to account for major revenue share in the global thyroid cancer market. The end use segment is divided into hospital laboratories, cancer diagnostic centers, research institutes, and others. Among end use the hospital segment is expected to account for major revenue share in the target market. The players profiled in the report are Abbott, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Siemens Healthcare GmbH, Bio-Rad Laboratories, Inc, General Electric, Koninklijke Philips N.V., Toshiba Corporation, Agilent Technologies, Inc., and Illumina, Inc. DOWNLOAD SAMPLE PAGES OF THIS REPORT@ https://www.acumenresearchandconsulting.com/request-sample/2574 Papillary Thyroid Carcinoma Papillary thyroid carcinoma is the most widely recognized thyroid malignant growth. About 80% of all thyroid malignancies cases are papillary thyroid cancer. Most generally, papillary thyroid malignant growths are absolutely asymptomatic. Nonetheless, the most widely recognized manifestation is a mass in the neck. Papillary carcinoma regularly emerges as a strong, sporadic, or cystic mass that comes from in any case ordinary thyroid tissue. This kind of malignant growth has a high fix rate—10-year endurance rates for all patients with papillary thyroid disease assessed at more than 90%. Cervical metastasis (spread to lymph hubs in the neck) are available in half of little papillary carcinomas and in over 75% of the bigger papillary thyroid carcinomas. The presence of lymph hub metastasis in the neck region regularly has a more successive repeat rate however not a higher death rate. Far off spread of papillary thyroid disease is called metastasis. Inaccessible metastasis of papillary thyroid disease is extraordinary, yet when it happens, it might spread to the lungs, liver, and bone. Papillary thyroid tumors that attack the encompassing tissues close to the thyroid organ have much more regrettable anticipation in view of a high neighborhood repeat rate. VIEW TABLE OF CONTENT OF THIS REPORT@ https://www.acumenresearchandconsulting.com/thyroid-cancer-market Follicular Thyroid Cancer About 15% of all thyroid disease cases are follicular thyroid cancer.1 Follicular carcinoma is viewed as more threatening (forceful) than papillary carcinoma. However, what are some normal follicular thyroid malignant growth manifestations, and how is follicular thyroid disease analyzed? Follicular thyroid disease happens in a somewhat more established age bunch than papillary thyroid malignant growth and is likewise more uncommon in youngsters. As opposed to papillary malignant growth, it happens just once in a while after radiation treatment. Mortality is identified with the level of vascular intrusion. Age is a vital factor as far as anticipation. Patients more seasoned than 40 years of age have a more forceful sickness and normally the tumor doesn't focus iodine just as in more youthful patients. Vascular attack is a trademark for follicular carcinoma and in this manner removed metastasis is more normal. With follicular thyroid malignancy, lung, bone, cerebrum, liver, bladder, and skin are expected locales of inaccessible spread. Lymph hub inclusion is undeniably more uncommon than in papillary carcinoma. Browse Upcoming Market Research Reports@ https://www.acumenresearchandconsulting.com/forthcoming-reports Segment Analysis by Region North America market is expected to account for major revenue share in the global thyroid cancer market due to high patient pool suffering from thyroid cancer. In addition, presence of large number of players operating in the country and introduction on innovative solutions are factors expected to support the growth of the thyroid cancer market. Asia Pacific market is expected to witness faster growth in the target market due to increasing awareness among consumers related to thyroid treatment. In addition, increasing government spending on the healthcare sector and flourishing healthcare tourism in developing countries are factors expected to augment the thyroid cancer market growth. Favorable business policies by the government and the emergence of small & mid-size enterprises with innovative solutions are factors expected to support the regional market growth. Competitive Landscape The global thyroid cancer market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/2574 BUY THIS PREMIUM RESEARCH REPORT - https://www.acumenresearchandconsulting.com/buy-now/0/2574 Would like to place an order or any question, please feel free to contact at firstname.lastname@example.org | +1 407 915 4157 For Latest Update Follow Us: https://twitter.com/AcumenRC https://www.facebook.com/acumenresearchandconsulting https://www.linkedin.com/company/acumen-research-and-consulting
The "Global EPDM Market by Application (Automotive, Building & Construction, Plastic Modification, Tires & Tubes, Wires & Cables, Lubricant Additives) and Region (North America, Europe, Asia-Pacific, Middle East & Africa, South America) - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
Automotive Paints Market Research Report by Paint Type (Basecoat, Clearcoat, Electrocoat, and Primer), by Painting Equipment Type (Airless Spray Gun and Electrostatic Spray Gun), by Technology, by Content, by Texture, by Resin Type, by Vehicle Type - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, April 20, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Automotive Paints Market Research Report by Paint Type, by Painting Equipment Type, by Technology, by Content, by Texture, by Resin Type, by Vehicle Type - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06063011/?utm_source=GNW Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Automotive Paints Market is expected to grow from USD 7,846.28 Million in 2020 to USD 9,585.59 Million by the end of 2025.2. The Global Automotive Paints Market is expected to grow from EUR 6,879.76 Million in 2020 to EUR 8,404.82 Million by the end of 2025.3. The Global Automotive Paints Market is expected to grow from GBP 6,116.12 Million in 2020 to GBP 7,471.90 Million by the end of 2025.4. The Global Automotive Paints Market is expected to grow from JPY 837,396.90 Million in 2020 to JPY 1,023,025.35 Million by the end of 2025.5. The Global Automotive Paints Market is expected to grow from AUD 11,393.84 Million in 2020 to AUD 13,919.55 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the Automotive Paints to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Paint Type, the Automotive Paints Market studied across Basecoat, Clearcoat, Electrocoat, and Primer. Based on Painting Equipment Type, the Automotive Paints Market studied across Airless Spray Gun and Electrostatic Spray Gun. Based on Technology, the Automotive Paints Market studied across Powder Coating, Solvent-borne, and Waterborne. Based on Content, the Automotive Paints Market studied across Electrocoat, Solvent-borne Paints, and Waterborne Paints. Based on Texture, the Automotive Paints Market studied across Matte Finish Paints, Metallic Texture, Pearlescent Paints, Solar Reflective Paints, and Solid Texture. Based on Resin Type, the Automotive Paints Market studied across Acrylic, Epoxy, and Polyurethane. Based on Vehicle Type, the Automotive Paints Market studied across Heavy Commercial Vehicle, Light Commercial Vehicle, and Passenger Cars. Based on Geography, the Automotive Paints Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Automotive Paints Market including Akzo Nobel N.V., Axalta Coating Systems, B&D Automotive Paint Supply, LLC, BASF SE, Berger Paints India Ltd, Cabot Corporation, Covestro AG, Donglai Coating Technology ?Shanghai? Co., Ltd., Dow Chemical Company, Eastman Chemical Company, Fabula Coatings India Pvt. Ltd., Jotun, Kansai Paint Co., Ltd, KC Co. Ltd, KCC Corporation, Kwality Paints and Coatings Pvt. Ltd., Nippon Paint Holdings Co., Ltd, PPG Industries, Inc., S.Coat Co., Ltd, Sheenlac Paints Ltd, Sirrus, Inc., Solvay S.A., The 3M Company, and Wanda Refinish. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Automotive Paints Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Automotive Paints Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Automotive Paints Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Automotive Paints Market?4. What is the competitive strategic window for opportunities in the Global Automotive Paints Market?5. What are the technology trends and regulatory frameworks in the Global Automotive Paints Market?6. What are the modes and strategic moves considered suitable for entering the Global Automotive Paints Market?Read the full report: https://www.reportlinker.com/p06063011/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
The "HER2 Antibodies - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
European CyberKnife Center to be Among the First Providers in the World to Offer the Latest Advance in Gyroscopic Radiosurgery
MARYSVILLE, Ohio, April 20, 2021 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE SMG), one of the world’s largest marketers of branded consumer lawn and garden products, will release its second quarter financial results on Wednesday, May 5, 2021, prior to the opening of the U.S. financial markets. The Company will host a conference call to discuss those results at 9:00 a.m. ET. To participate in the conference call, please call 800-289-0438 (Conference Code: 5691876). A replay of the call can be heard by calling 888-203-1112. The replay will be available for 15 days. A live webcast of the call and the press release will be available on the Company’s investor relations website at http://investor.scotts.com. An archive of the press release and any accompanying information will remain available for at least a 12-month period. About ScottsMiracle-Gro With approximately $4.1 billion in sales, the Company is one of the world’s largest marketers of branded consumer products for lawn and garden care. The Company’s brands are among the most recognized in the industry. The Company’s Scotts®, Miracle-Gro® and Ortho® brands are market leading in their categories. The Company’s wholly-owned subsidiary, The Hawthorne Gardening Company, is a leading provider of nutrients, lighting and other materials used in the indoor and hydroponic growing segment. For additional information, visit us at www.scottsmiraclegro.com. Contact: Jim King Executive Vice President Investor Relations & Corporate Affairs (937) 578-5622
WWF-Canada report shows that a lack of national and international regulations is preventing significant greenhouse-gas reductionsToronto, April 20, 2021 (GLOBE NEWSWIRE) -- A new report commissioned by WWF-Canada found that in 2019, the 6078 vessels that operated in Canadian waters emitted eight million tons of CO2 — the equivalent of almost two coal-fired plants in one year. They also emitted 150,000 tons of nitrogen oxides, particulate matter, black carbon and sulphur oxides combined. Despite these numbers, Canada has largely overlooked regulating greenhouse gas (GHG) emissions in the shipping industry, waiting instead for the International Maritime Organization (IMO) to set a framework for domestic and international emission reductions — something that has not been realized. The lack of such a framework sets Canada back in reaching its international emissions reduction commitments and increases the ongoing threats of climate change and threats to coastal communities and ocean health. However, the report also shows that there is opportunity and imperative for significant emissions reductions domestically. About 10 per cent of the ships that spent most of their time in Canadian waters were responsible for 30 per cent of the country’s overall shipping-related CO2 emissions. National policy and regulatory tools could effectively reduce a significant portion of national emissions. “If we’re going to reach our international commitments to reduce GHG emissions by 30 per cent by 2030, we need to use all of the national tools at our disposal. Canada needs to come up with a plan that includes targets and timelines for reducing absolute emissions, and incentives for using alternative fuels and technologies,” says WWF-Canada’s Andrew Dumbrille, lead specialist, marine shipping and conservation. The report also outlines how to target these measures. Bulk carriers, containerships and cruise ships were the largest contributors to emissions. Some of these fleets are made up of older ships, which could be replaced by electric vessels or a combination of alternative fuels. Other measures, such as speed reductions, also lower GHG emissions and help prevent underwater noise and ship strikes, which remain significant threats to marine wildlife. For example, a 10 per cent reduction in speed becomes a 19 per cent reduction in GHG emissions and a 40 per cent reduction in underwater noise pollution. To meet national GHG reduction commitments, Canada’s energy transition needs to include all industry sectors, including shipping. The shipping industry has great potential to lead the way or get left behind. About World Wildlife Fund Canada WWF-Canada creates solutions to the environmental challenges that matter most for Canadians. We work in places that are unique and ecologically important, so that nature, wildlife and people thrive together. Because we are all wildlife. For more information, visit wwf.ca. CONTACT: WWF-Canada firstname.lastname@example.org
Data Published in The CRISPR Journal Describe Inlaid Base Editors (IBEs) that Enhance Editing Efficiency and Capability, an Advancement of the Company’s Pioneering Work in Developing Base Editors Data Demonstrates Utility of IBEs in BEAM-102, Enabling Conversion of Sickle Cell Hemoglobin Allele to the Naturally Occurring, Benign HbG-Makassar Variant in Patient-derived Hematopoietic Stem Cells CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the publication of work describing inlaid base editors (IBEs) in The CRISPR Journal. IBEs are architectural variants of base editors that have attributes of enhanced specificity and altered activity windows relative to foundational base editors. The work highlights Beam’s application of its IBEs for BEAM-102, one of its base editing programs in development for the treatment of sickle cell disease (SCD). IBEs are an important innovation enabled by Beam’s extensive know-how and understanding of structural biology and protein-guided DNA-targeting, which adds to the company’s ever-expanding genome editing toolbox. Notably, the predictable, shifted editing window enabled by IBEs aids in further addressing disease-causing mutations normally out of reach with canonical base editors, with high efficiency and minimized off-target effects on the genome. “Beam is a pioneer in the field of base editing, and this work is a testament to the leadership of our team of scientists in expanding the role that base editing medicines can play in the treatment of a wide variety of diseases,” said Giuseppe Ciaramella, Ph.D., president and chief scientific officer of Beam. “Direct correction of the sickle-causing mutation with traditional gene editing technologies has been limited by low efficiency. The therapeutic potential of our rationally designed IBEs is exciting. Not only have these differentiated base editors demonstrated the potential to efficiently convert the disease-causing sickle hemoglobin allele into a normal variant; they open the doors to potentially target a broad range of other genetic diseases.” Beam’s base editors use a DNA-targeted deaminase to create a precise chemical modification of a target DNA base with high precision and limited off-target consequences. IBEs expand the breadth of potential base editing targets by extending the range of editing windows that can be created for any given CRISPR-Cas protein used to target the DNA. By inserting the deaminase into the CRISPR protein at various strategic positions, repositioning the deaminase’s active site, IBEs enable editing outside the traditional editing window. The broad modularity of these proprietary base editor designs was demonstrated using both the adenine base editor (ABE) and the cytosine base editor (CBE). Potential Utility of Beam’s IBEs in BEAM-102 BEAM-102 aims to treat SCD by directly editing the causative sickle hemoglobin (HbS) point mutation to recreate a naturally occurring normal human hemoglobin variant, HbG-Makassar. The Makassar variant has been reported to have the same function as the wild-type (HbA) allele and does not cause SCD. Findings in the paper show that Beam’s IBE resulted in highly efficient editing levels of over 70% in CD34+ cells from both sickle trait (HbAS) and sickle cell disease (HbSS) individuals. Additionally, the IBE demonstrated significantly reduced guide-independent off-target editing in vitro. “Beam was launched in 2017 by world-leading innovators in gene editing who discovered that base editing is capable of making single-base changes with high efficiency and precise control of editing outcomes,” said John Evans, chief executive officer of Beam Therapeutics. “With the development of our IBEs, we have once again set a precedent for the expansion and advancement of base editing as a new generation of gene editing technology. In addition, the patent applications on this work complement and extend Beam’s comprehensive patent portfolio in the field of base editing. We are dedicated to fully realizing the potential of this technology for patients as we advance our portfolio, with plans to submit what we expect will be the first IND application for a base editor program in the second half of 2021.” About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the expected timing of filing our first investigational new drug application, our ability to advance programs to the clinic; and the therapeutic applications and potential of our technology, including our IBEs and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the potential impact of the COVID-19 pandemic; that preclinical testing of our product candidates and preliminary or interim data from preclinical and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that enrollment of our clinical trials may take longer than expected; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Contacts: Investors:Chelcie ListerTHRUST Strategic Communicationschelcie@thrustsc.com Media:Dan Budwick1ABdan@1abmedia.com
Byrider Direct, along with the traditional Byrider franchise model, provides multiple entry points into the profitable 30-year franchise system Byrider franchise location, Fond du Lac, WI. Carmel, IND, April 20, 2021 (GLOBE NEWSWIRE) -- Byrider, the only buy-here-pay-here used car and finance franchised dealership in America, today, announced the launch of its new franchising model, Byrider Direct, adding a new, simpler entry point into its successful franchising system, with a lower initial investment that focuses exclusively on sales and service. “Our team is excited to offer a new pathway to join in Byrider’s success,” said Byrider CEO, Craig Peters. “Underwriting and servicing a portfolio can be a very complex and capital-intensive part of the buy-here-pay-here business model. Byrider Direct addresses those potential challenges by allowing new franchisees to focus on retail and gives them a new access point in line with their experience and comfort level as they invest in a new partnership with us.” Alongside Byrider’s popular and profitable traditional model, Byrider Direct provides franchisees the opportunity to focus solely on the retail side (sales and service) and still garner strong returns. Byrider Direct requires a lower capital investment and provides finance and portfolio support that will allow a new franchisee to truly harness the learned expertise of Byrider’s decades-long success. “Byrider Direct is a leaner, meaner version of the traditional Byrider model, and it comes with everything a potential franchisee would expect, minus the financing arm,” said Jack Humbert, Vice President of Franchise Development at Byrider. “We’re engaging new investors with expanded investment level ranges to provide multiple options of entry to build a dealership and help consumers get a fresh opportunity to finance and own a quality vehicle.” The traditional franchise model continues to be an incredibly strong performer, requiring an estimated initial investment of around $1 million, allowing the franchisee full management of all operations, including underwriting and collection. Exclusive territories are currently available for both Byrider Direct and Byrider's traditional franchise offering. About Byrider: Byrider, one of America’s largest buy-here-pay-here used car dealership and franchise systems, has sold more than 1.33 million cars at more than 140 locations across the country. Founded in 1989 as J.D. Byrider, the company recently rebranded and changed its name to Byrider. As part of its commitment to customer service, Byrider offers high-quality autos, trucks, and SUVs with on-site financing and features warranties and optional vehicle service plans with each vehicle sold. Each Byrider store features a state-of-the-art service department offering low-cost maintenance. Consumers who have been turned down for traditional bank financing are often able to “Buy, Finance and Drive On” with Byrider at www.byrider.com. Attachment WI117-Fond-du-Lac-2-3-scaled CONTACT: Zach Zagar Byrider 3172493180 email@example.com Jack Humbert Byrider Franchising 317-402-2458 firstname.lastname@example.org
DISQO Co-Founder & CMO Armen Petrosian to Interview General Mills CMO Ivan Pollard on April 21LOS ANGELES, April 20, 2021 (GLOBE NEWSWIRE) -- Audience insights platform DISQO today announced its sponsorship of the TMRE Connects Brand Insights Summit series. At the event which will be held virtually on April 21, 2021, Armen Petrosian, co-founder and CMO of DISQO, will have an intimate conversation about brand purpose with Ivan Pollard, global CMO of General Mills. “The Summit is where big brands share breakthrough ideas and demonstrate their deeper vision to be a driving force for good. DISQO was built with a purpose-led approach as we innovate ethics-based technologies for consumer data and insights. Thus, we’re proud to help bring these stories to the industry,” Petrosian said. “My conversation with Ivan is a chance to hear how one of the most successful brands in the world thinks about its purpose with people. I look forward to learning more about how research drives purpose in Ivan’s brand building efforts for General Mills.” Hosted by Informa PLC, TMRE Connects: Brand, Insight & Innovation is a client-side only quarterly meet-up where brand and research leaders discuss how to leverage customer insights to fuel innovative new ideas. To request an invitation to the conversation, please visit the TMRE Connects: Brand, Insight & Innovation registration page. About DISQO DISQO is an audience insights platform fueling breakthrough ideas with complete and actionable insights into human expression and experience. DISQO offers a transparent knowledge exchange between business clients and 10M+ consumer members rewarded for openly sharing information. A platform as a service built on an ethical, permission-based technology foundation, DISQO offers automated and managed services to query its member community and learn from their consumer journeys. Founded in 2015 and headquartered in Glendale, CA, DISQO is recognized as a fast-growing technology firm and a great place to work, now with more than 200 employees. Learn more at www.DISQO.com About Informa PLCInforma is a leading international Information Services, Advanced Learning, B2B Exhibitions and Events Group. It helps commercial, professional and academic communities work smarter and make better decisions faster, through specialist content and intelligence, and opportunities to connect and learn. For more information, please visit www.informa.com. ContactMichael ShmarakBlast PR for DISQO312.email@example.com
Cannabis Pharmaceuticals Market Research Report by Brand (Epidiolex and Sativex) - Global Forecast to 2025 - Cumulative Impact of COVID-19 Market Statistics:New York, April 20, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cannabis Pharmaceuticals Market Research Report by Brand - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06063012/?utm_source=GNW The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Cannabis Pharmaceuticals Market is expected to grow from USD 872.57 Million in 2020 to USD 1,972.67 Million by the end of 2025.2. The Global Cannabis Pharmaceuticals Market is expected to grow from EUR 765.09 Million in 2020 to EUR 1,729.68 Million by the end of 2025.3. The Global Cannabis Pharmaceuticals Market is expected to grow from GBP 680.17 Million in 2020 to GBP 1,537.69 Million by the end of 2025.4. The Global Cannabis Pharmaceuticals Market is expected to grow from JPY 93,126.28 Million in 2020 to JPY 210,534.83 Million by the end of 2025.5. The Global Cannabis Pharmaceuticals Market is expected to grow from AUD 1,267.10 Million in 2020 to AUD 2,864.59 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the Cannabis Pharmaceuticals to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Brand , the Cannabis Pharmaceuticals Market studied across Epidiolex and Sativex. Based on Geography, the Cannabis Pharmaceuticals Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cannabis Pharmaceuticals Market including AbbVie Inc., Amyris, Inc., Aphria, Inc., Aurora Cannabis, Inc., Botanix Pharmaceuticals, Breath of Life Pharma, Ltd., Cannabis Science, Inc., Canopy Growth Corporation, Cara Therapeutics, CB Therapeutics Inc., Corbus Pharmaceuticals Holdings, Inc., Cronos Group Inc., GW Pharmaceuticals, PLC, Insys Therapeutics, Inc., Medical Marijuana Inc., Medicure Pharmaceuticals, MedReleaf Corp., MGC Pharmaceuticals Limited, Pascal Biosciences Inc., PharmaCyte Biotech, Inc., Serina Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Tilray, Inc., Valeant Pharmaceuticals, and Zynerba Pharmaceuticals, Inc.. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cannabis Pharmaceuticals Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Cannabis Pharmaceuticals Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cannabis Pharmaceuticals Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cannabis Pharmaceuticals Market?4. What is the competitive strategic window for opportunities in the Global Cannabis Pharmaceuticals Market?5. What are the technology trends and regulatory frameworks in the Global Cannabis Pharmaceuticals Market?6. What are the modes and strategic moves considered suitable for entering the Global Cannabis Pharmaceuticals Market?Read the full report: https://www.reportlinker.com/p06063012/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
The "Businesses Need Receivables Automation to Keep Cash Flow Positive During the Pandemic Recovery" report has been added to ResearchAndMarkets.com's offering.
Tim Walz says local and state resources ‘exhausted’ by Brooklyn Centre killing
(Bloomberg) -- Tobacco stocks plunged after a report said the U.S. government may only allow cigarettes with nicotine levels so low they’d no longer be addictive, and may also move to ban menthol.The U.S. Food and Drug Administration is expected to rule on menthol cigarettes by the end of the month under pressure from a deadline in a lawsuit. The agency said years ago it would consider lowering nicotine levels in cigarettes. The Wall Street Journal reported Monday that the Biden administration agency is considering the ban, along with requirements to lower nicotine content, citing people familiar with the matter.Marlboro producer Altria Group Inc. fell as much as 6.9% Tuesday, losing more than $11 billion in market value since Friday. British American Tobacco Plc dropped as much as 8.3% in London Tuesday. Analysts estimate the maker of Lucky Strike cigarettes gets as much as a third of its earnings from menthol brands such as Newport.The FDA declined to comment on the report on Monday. The Wall Street Journal said the Biden administration is weighing whether to enact a menthol ban or nicotine restrictions, or both.Imperial Brands Plc, which makes Kool cigarettes, fell as much as 7.5%. Stock of 22nd Century Group Inc., which already sells cigarettes with very low nicotine levels, extended Monday’s 11% gain.The industry has been anticipating an FDA decision about nicotine levels in cigarettes for years. The agency declared in 2018 that it intended to do so, prompting Altria to question whether that’s technically achievable and if that would effectively reduce smoking. Since then, 22nd Century Group, based in Williamsville, New York, has come out with reduced-nicotine cigarettes.Philip Morris International Inc. was little changed Tuesday after raising its outlook for the year amid stronger demand for its IQOS cigarette alternative. Philip Morris, which doesn’t sell cigarettes in the U.S., dropped only 1.3% Monday, outperforming rivals on the prospect that tighter tobacco rules could spur demand for IQOS. Altria sells the product in the U.S. through an alliance.What Bloomberg Intelligence SaysThe notion of a federal mandate to cut nicotine levels in U.S. cigarettes would impair Altria most, considering it controls 53% of the $90 billion domestic market, though we believe such a requirement would be years away and face fierce legal challenges.-- Kenneth Shea, BI senior analystIn an email, Altria said any FDA action “must be based on science and evidence and must consider the real-world consequences of such actions, including the growth of an illicit market and the impact on hundreds of thousands of jobs.”The proposal on nicotine is serious, but politically would be difficult to pull off, according to Adam Spielman, an analyst at Citigroup. Some 15% of voters smoke, and such a move could cost Democrats large numbers of blue-collar votes.“We suspect that this idea will continue to be discussed for decades, but we would be extremely surprised if it were implemented in the next 10 or even 15 years,” he wrote in a note.BAT’s Reynolds unit said there are better ways to improve public health and reduce the harm from tobacco.“Many consumers wrongly believe that a cigarette very low in nicotine content is lower in risk than traditional cigarettes, a misconception that poses a major hurdle in determining proposed rulemaking for low nicotine cigarettes,” the company said.One issue is that such a rule might lead some smokers to consume more cigarettes as they seek a fix to their nicotine cravings, inhaling more dangerous chemicals in the process. It could also create a black market for more powerful cigarettes.The FDA has been expected to state its position on whether it would still allow menthol cigarettes by April 29, under a deadline imposed by a lawsuit. The case, brought by the African American Tobacco Control Leadership Council, had sued the government agency saying it had taken an unreasonably long time to respond to a citizen’s petition filed years ago that sought to prohibit menthol as a flavor in cigarettes.(Updates shares in third paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Key Players Covered in the North America Feeding Tubes Market are Cardinal Health (Ohio, United States), BD (Becton, Dickinson and Company) (New Jersey, United States), B. Braun Melsungen AG (Melsungen, Germany), Avanos Medical Inc (Georgia, United States), Baxter (Deerfield, United States), Vygon SA (Écouen, France), Applied Medical Technology, Inc. (Ohio, United States), Other Prominent PlayersPune, India, April 20, 2021 (GLOBE NEWSWIRE) -- The North America feeding tubes market is set to gain momentum from the increasing shift of people towards enteral feeding from parenteral feeding because of its several benefits. It promotes the local immune function of the gut and eliminates villous atrophy. Hence, manufacturers nowadays are developing novel products to cater to the high demand. In June 2020, for instance, Applied Medical Technology, Inc. (AMT) introduced AMT ONE Source™, its latest mobile app to offer easy and quick access to the company’s educational materials. This information is given by Fortune Business Insights™ in a new report, titled, “North America Feeding Tubes Market, 2021-2028.” As per the report, the North America feeding tubes market size is expected to grow from USD 516.1 million in 2020 to USD 1,014.9 million in 2028 growing at a CAGR of 7.9% in the forecast period. The market stood at USD 397.0 million in 2019. Request a Sample Copy of the Research Report https://www.fortunebusinessinsights.com/enquiry/sample/north-america-feeding-tubes-market-105112 COVID-19 Pandemic: Rising ICU Admissions in 2020 Has Affected Growth Positively The COVID-19 pandemic affected the North America feeding tubes industry positively in 2020 because of the rising number of ICU admissions. The surging cases of coronavirus resulted in the increasing admission of patients in the ICU, especially in the U.S. These patients require enteral feeding as they are incapable of chewing and swallowing food on their own. We are providing detailed research reports to help you better understand the current scenario of the market. To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/north-america-feeding-tubes-market-105112 Segmentation- Diabetes Segment Generated 13.9% Share in 2020 Based on the type, the market for North America feeding tubes is divided into nasogastric tube, nasojejunal feeding tube, gastric tube (G tube), jejunostomy tube (J tube), and orogastric tube. By age, it is segregated into pediatric and adult. Based on the application, it is fragmented into diabetes, gastroenterology, oncology, and others. Out of these, the diabetes segment earned 13.9% in terms of the North America feeding tubes market share in 2020. This growth is attributable to the rising prevalence of diabetes in the U.S. requiring enteral feeding. Based on end-users, the market is classified into homecare, specialty clinics, hospitals, and others. Lastly, by geography, it is bifurcated into Canada and the U.S. Quick Buy North America Feeding Tubes Market https://www.fortunebusinessinsights.com/checkout-page/105112 Report Coverage- We have conducted extensive primary and secondary research to collect data about numerous aspects of the market for North America feeding tubes. We have also conducted interviews with marketing managers, sales managers, product managers, and C-level executives to derive insights, such as raw material supply & demand, application patterns, growth rate, and average pricing. Drivers & Restraints- Urgent Need to Feed Children with Chronic Illnesses will Favor Growth Feeding tubes are gaining more traction from pediatrics. These are considered to be an essential alternative for children living with chronic illnesses. These tubes help them to easily ingest food. But, medical professionals often face various issues, such as tube placement errors during tube feeding. Therefore, several companies present in the North America feeding tubes industry are conducting research and development activities to introduce innovative feeding tube systems. However, rising number of product recalls on account of manufacturing defects may hamper the North America feeding tubes market growth in the upcoming years. For instance, in July 2020, the U.S. FDA recalled Kentec Medical, Inc.’s Ameritus Medical Products ENFit polyurethane and silicone feeding tubes because of the possibility of breakage or fracture. It would have caused serious health hazards. Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/north-america-feeding-tubes-market-105112 Competitive Landscape- Key Players Focus on New Product Development to Satiate Demand from Healthcare Sector The market for North America feeding tubes is partially consolidated with significant companies, such as Becton, Dickinson and Company (BD), B. Braun Melsungen AG, Baxter, and Cardinal Health accounting for the major share. They are majorly focusing on new product development to fulfil the rising demand from the healthcare sector in the U.S. and Canada. Below is one of the latest industry developments: July 2020: Baxter International Inc. signed an agreement for commercializing the VIPUN Gastric Monitoring System. It possesses a smart enteral feeding tube that can effectively measure stomach motility. This unique feature will aid clinicians in detecting enteral feeding intolerance and make better decisions related to nutrition therapy. A list of prominent North America feeding tubes manufacturers operating in the market: Cardinal Health (Ohio, United States)BD (Becton, Dickinson and Company) (New Jersey, United States)B. Braun Melsungen AG (Melsungen, Germany)Avanos Medical Inc (Georgia, United States)Baxter (Deerfield, United States)Vygon SA (Écouen, France)Applied Medical Technology, Inc. (Ohio, United States)Other Prominent Players Have Any Query? Ask Our Experts https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/north-america-feeding-tubes-market-105112 Table of Contents Introduction Research ScopeMarket SegmentationResearch MethodologyDefinitions and Assumptions Executive SummaryMarket Dynamics Market DriversMarket RestraintsMarket Opportunities Key Insights Prevalence of Key Indications (Cancer, Diabetes, Gastric Disorders), North AmericaNew Product Launches, By Key PlayersList of Key Distributors of Major PlayersOverview of Distribution Channel in North AmericaImpact of COVID-19 on the marketAverage Selling Prices, Key Players / OEMsKey Industry Developments (Mergers, Acquisitions, and Partnerships)North America Feeding Tubes Market by G-Tubes North America Feeding Tubes Market Analysis, Insights and Forecast, 2017-2028Key Findings / SummaryMarket Analysis, Insights and Forecast – By Type Nasogastric tubeNasojejunal feeding tubeGastric Tube (G tube)Jejunostomy Tube (J tube)Orogastric tube ToC Continue… Have a Look at Related Reports: Adult Diapers market Size, Share & Industry Analysis, By Product Type (Underwear & Briefs, Pads & Guards, and Drip Collectors & Bed Protectors), By Gender (Male and Female) By Distribution Channel (Institutional Sales, Retail Stores, and Online Channels) and Regional Forecast, 2019-2026 Recombinant Vaccines market Size, Share & COVID-19 Impact Analysis, By Type (Subunit and Live Attenuated), By Route of Administration (Parenteral and Oral), By Disease Indication (Human Papillomavirus (HPV), Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Geography Forecast, 2020-2027 Germany Pneumococcal Vaccines market Size, Share & Industry Analysis, By Product Type (PCV10, PCV13, and PPSV23), By End User (Hospitals, Clinics, and Others) and Region Forecast, 2019-2026 Diabetic Foot Ulcer Treatment market Size, Share & Covid-19 Impact Analysis, By Ulcer Type (Neuropathic Ulcer, Ischemic Ulcer, Neuro-ischemic Ulcer), By Product (Wound-care Dressings, Wound-care Devices, Active Therapies, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Homecare Settings), and Regional Forecast, 2020-2027 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India. Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email:email@example.com LinkedIn | Twitter | Blogs
Aid your post-workout recovery and soothe muscle aches with this lightweight device
Samir Jassal is also a former parliamentary candidate and councillor who has campaigned with Boris Johnson